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Background to clarify the role of angiotensin II (Ang II) in insulin-induced arteriosclerosis, we examined the effects of Ang II on insulin-induced mitogen-activated protein (MAP) kinase activation and cellular hypertrophy in rat vascular smooth muscle cells (VSMcs).
methodS
Phosphorylated MAP kinases were detected with western blot analysis. cellular hypertrophy and glucose uptake were evaluated from incorporation of [ 3 H]-labeled-leucine and -deoxy-D-glucose, respectively. cell sizes were measured by coulter counter. 
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Insulin Signal Shift via Ang II cells (VSMCs). However, systemic glucose metabolism is mostly regulated in skeletal muscle, adipose tissue and liver. 11 Therefore, vasculature's role in glucose metabolism is considered to be minor, and the role of insulin signaling in vasculature is still controversial. Considering the evidence mentioned above, we hypothesized that Ang II reduces glucose metabolic insulin signals via IRS-1 depletion, causing diversion of insulin signals into the cell hypertrophic pathway mediated by MAP kinase activation in VSMCs. To test this hypothesis, we examined the effects of Ang II on the VSMC insulin signaling pathways, including IRS-1-Akt and MAP kinase, glucose metabolism and hypertrophic changes.
methodS
Materials. Anti-IRS-1 antibody was purchased from BD Biosciences (Franklin Lakes, NJ). Antibodies to phosphoextracellular regulated kinase (ERK) 1/2, phospho-p38MAP kinase, phospho-c-Jun N-terminal kinase (JNK), phosphoAkt, ERK 1/2, p38MAP kinase, JNK, and Akt were purchased from Cell Signaling Technology (Beverly, MA). RNH-6270 (an active olmesartan metabolite) was provided by Daiichi Sankyo (Tokyo, Japan). All other chemicals and reagents, including insulin, Ang II and Dulbecco's modified Eagle's medium (DMEM) with 25 mmol/l Hepes and 4.5 g/l glucose, came from Sigma-Aldrich (St Louis, MO).
Cell culture. VSMCs were isolated, using enzymatic digestion, from thoracic aortae of 4-week-old, male Sprague-Dawley rats, as previously described. 12 All experimental procedures were performed according to the guidelines for the care and use of animals established by Kagawa University. Cells were grown in DMEM supplemented with 10% fetal bovine serum (HyClone, Logan, UT), penicillin (100 U/ml, Life Technologies, Carlsbad, CA) and streptomycin (100 μg/ ml, Life Technologies) at 37 °C under 5% CO 2 /95% air in a humidified incubator. VSMCs were used for experiments between their third and eight passages.
Small interfering RNA (siRNA) transfection experiments. The method of transfecting of VSMCs with siRNA was previously described. 13 Stealth Select RNAi pre-designed against IRS-1 was synthesized by Life Technologies. The negative control, nontargeting scrambled siRNA was purchased from Life Technologies. The VSMCs were transfected with Lipofectamine 2000 (Life Technologies) and 30 pmol of siRNA for 48 h, according to the manufacturer's protocol.
Western blot analysis. Cells at 80-90% confluence were made quiescent by incubation with DMEM containing 0.1% fetal bovine serum for 24 h. Cells were stimulated with agonists at 37 °C in serum-free DMEM, lysed as described previously; 6 solubilized proteins were isolated by centrifugation and quantified by the Bradford assay. Proteins were separated using SDS-polyacrylamide gel electrophoresis (6% polyacrylamide gel for IRS-1 and 10% gel for MAP kinase and Akt), and transferred to nitrocellulose membranes. After blocking, blots were incubated with primary antibodies; proteins were detected by enhanced chemiluminescence (GE Healthcare, Buckinghamshire, UK). To confirm equal protein loading, each membrane was reprobed with anti-β-actin antibody (SigmaAldrich). Band intensities were quantified by immunoblot densitometry, using NIH ImageJ software.
Dihydroethidium staining. The oxidative fluorescence dihydroethidium was used to evaluate intracellular O 2 -levels as described previously. 14 [ 3 H]-leucine incorporation and glucose uptake. Protein synthesis was assessed by measuring [ 3 H]-leucine incorporation. In brief, quiescent VSMCs were cultured in 6-well plates, then treated with insulin (2-100 nmol/l) containing 1 μCi/ ml [ 3 H]-leucine for 24 h. After labeling, cells were washed twice with phosphate-buffered saline and twice with icecold 5% trichloroacetic acid to remove the unincorporated [ 3 H]-leucine, solubilized in 500 μl of 0.25 mol/l NaOH containing 0.1% SDS and neutralized. Aliquots of the samples were added to 10 ml of scintillation fluid and counted in a scintillation counter.
Glucose uptake was determined as previously described. 15 Serum-starved VSMCs, with or without Ang II stimulation, were incubated in Krebs-Ringer-HEPES buffer for 2 h. Cells were incubated with insulin (10 nmol/l) for 30 min, and 0.2 mmol/l 2-deoxy-D-glucose containing 1 μCi/ml 2-deoxy-D-[ 3 H] glucose was added for another 30 min. Cells were disrupted, and amounts of labeled glucose that were taken up were determined by scintillation counting.
Cell volume measurement.
Cell volume measurements were performed by electronic sizing with a Coulter Counter Multisizer 3 (Beckman-Coulter, Miami, FL). Briefly, cells were washed in phosphate-buffered saline and lifted by incubation with 0.25% trypsin-EDTA (Life Technologies). Trypsin was inactivated adding of an equal volume of medium; cells were pelleted by brief centrifugation and resuspended in Isoton II Diluent (Beckman-Coulter). The range of cell sizes that could be effectively evaluated using the aperture was 10-100 μm. Cell size measurements were obtained every 10 s, and each measurement contained an average of 2,000 cells.
Statistical analysis.
Values are presented as means ± s.e. Multiple-group comparisons were made using one-way or two-way analyses of variance (ANOVA), followed by Bonferroni's test. Values of P < 0.05 were considered statistically significant. (Figure 1b) . However, in VSMCs transfected with scrambled siRNA, insulin had no significant effect on leucine incorporation. These results suggest that IRS-1 affects the insulin signaling pathway, and IRS-1 depletion augments insulin-induced hypertrophic alterations in VSMCs.
effects of ang ii pretreatment on insulin-induced phosphorylation of maP kinase
To evaluate effects of Ang II pretreatment on the insulin signaling pathway, we measured MAP kinase phosphorylation in VSMCs using western blot analysis. Concentration and pretreatment duration of Ang II (100 nmol/l, 18 h) were determined on the basis of results from previous studies in VSMCs. 6 Insulin (10 nmol/l, 5 min) significantly increased p38MAP kinase phosphorylation in Ang II (100 nmol/l, 18 h)-pretreated VSMCs (Figure 2a) . Pretreatment with Ang II augmented insulin-induced p38MAP kinase phosphorylation (Figure 2b) , and RNH-6270 (100 nmol/l), an ARB, completely inhibited Ang II-augmented p38 MAP kinase phosphorylation induced by insulin (Figure 2c) . Similarly, insulin-induced JNK phosphorylation was higher in Ang II-pretreated VSMCs (Figures 2d,e) . However, insulininduced ERK 1/2 phosphorylation was not affected by Ang II pretreatment (Figures 2f,g ). On the other hand, pretreatment with Ang II (100 nmol/l, 18 h) attenuated Akt phosphorylation induced by insulin (10 nmol/l, 5 min) in VSMCs (see Supplementary Figure S2 online). In addition, we used dihydroethidium fluorescence to evaluate reactive oxygen species (ROS) formation. We confirmed that Ang II augmented ROS formation in a time-dependent manner (see Supplementary  Figure S3 online).
effects of ang ii pretreatment on insulin-induced protein synthesis and cell volume
The MAP kinases, such as p38MAP kinase and JNK, are involved in protein synthesis and cell hypertrophy. 16 (Figure 3b) ; however, PD98059 (10 μmol/l), an ERK kinase inhibitor, decreased the leucine incorporation slightly but not significantly. Wortmannin (100 nmol/l), a phosphatidylinositol 3-kinase inhibitor, did not affect leucine incorporation induced by insulin. Use of RNH-6270 (100 nmol/l) or ebselen (40 μmol/l), an antioxidant, completely abolished the insulininduced leucine incorporation in Ang II-pretreated VSMCs.
We measured cell volume using a Coulter Cell Multisizer. Insulin (10 nmol/l, 24 h) significantly increased VSMC size (Figure 3c) . Pretreatment with Ang II augmented insulininduced cell enlargement compared with cells without Ang II pretreatment. The ARB treatment inhibited insulin-induced cell enlargement in Ang II-pretreated VSMCs. These results suggest that Ang II pretreatment augments insulin-induced protein synthesis and cell hypertrophy via AT 1 receptors, in oxidative stress-, p38MAP kinase-, and JNK-dependent manners.
effect of ang ii pretreatment on insulin-induced glucose uptake
We measured the uptake of 2-deoxy- 6 Although we have already demonstrated the crosstalk between MAP kinase and Akt pathways, 18 the present study advances these previous findings by showing that Ang II pretreatment shifts the insulin signaling pathway from glucose metabolism to cell hypertrophy and vascular remodeling (see Supplementary Figure S4 online). Hypertrophy of VSMCs is seen in various states of arteriosclerosis; 19 and vascular remodeling, including arteriosclerosis and cardiovascular disease, is a major diabetic complication. Our results provide a possible molecular mechanism of vascular remodeling induced by Ang II and insulin in diabetes mellitus. Insulin receptors are expressed in vasculature, including VSMCs. Although insulin exerts numerous effects via insulin receptors, 20 its physiological and pathological effects on vascular function are still controversial. Insulin regulates systemic glucose metabolism through glucose uptake into cells. In vasculature, although insulin increases intracellular glucose uptake, the glucose store in VSMCs is little compared to the whole body, thus, physiological effect of insulin on vascular glucose metabolism might be minimal. In addition, previous studies have revealed that insulin not only regulates glucose levels but also induces proatherosclerotic changes. 21 In this study, treatment with insulin alone induced MAP kinase activation, protein synthesis and enlargement of cell size in VSMCs, and more importantly, pretreatment with Ang II augmented proatherosclerotic changes induced by insulin via IRS-1 degradation and MAP kinase activation. Because incubation with Ang II alone did not induce these changes seen in the presence of both insulin and Ang II, IRS-1 degradation, MAP kinase activation and shift of insulin signaling could be 
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Insulin Signal Shift via Ang II necessary for insulin-induced proatherosclerotic changes in Ang II-pretreated VSMCs. Furthermore, as the insulin concentration used in this study was 2-100 nmol/l, while the physiological concentration is considered to be in the low nmol/l range in rodents, 22 we assumed that the hypertrophic effects occurred in this hyperinsulinemic setting, which is often seen in patients with insulin resistance. Taken together, these facts suggested that high insulin concentrations augment arteriosclerosis in patients with activation of renin-angiotensin system. Clinical trials have revealed that angiotensin-converting enzyme inhibitors 23 and ARBs 10 prevent arteriosclerosis and the onset of cardiovascular diseases in patients with type 2 diabetes mellitus, partially independently of their blood pressure-lowering effects. In addition, it has been already reported that ARBs attenuate arteriosclerotic changes without improving systemic glucose levels. 10 Although Ang II regulates blood pressure via vascular tone and modulation of water and electrolytes, it is not a major effector of glucose metabolism. Insulin, on the other hand, mainly regulates blood glucose via intracellular uptake of glucose, and insulin-induced vascular remodeling is still controversial in patients. Based on our previous and present results, we considered that Ang II leads to insulin signal diversion and vascular remodeling.
Oxidative stress is involved in the development of diabetic cardiovascular complications. 24 We have demonstrated that Ang II-induced oxidative stress attenuates glucose metabolism in VSMCs. 6 As shown in see Supplementary Figure S3 online and Figure 3b , Ang II augmented ROS formation, and an antioxidant completely inhibited insulin-induced hypertrophic effect in Ang II-pretreated VSMCs. In addition, p38MAP kinase and JNK, which were augmented in Ang II-pretreated VSMCs in this study, are known to be ROS sensitive. While oxidative stress directly modulates intracellular signaling pathways, with consequent atherosclerotic changes in diabetes mellitus, insulin diversion mediated by oxidative stress may induce further hypertrophic alterations.
In conclusion, Ang II attenuates insulin-induced glucose uptake and enhances vascular cell hypertrophy via an oxidative stress-mediated MAP kinase pathway in VSMCs. These results make clear that Ang II induces VSMC insulin resistance. We define VSMC insulin resistance to be an insulin-induced vascular state in which signal recognition required for glucose metabolism is incomplete, accompanying progressive remodeling. In addition, recent reports suggested that vascular insulin resistance is considered to be involved in atherogenic modulation and subsequent cardiovascular events. 25 Thus, prevention of vascular insulin resistance may be a therapeutic target for cardiovascular complications in diabetic patients. It is highly probable that Ang II may shift insulin signaling from glucose metabolism to vascular remodeling, which may be involved in high concentration of insulin-induced arteriosclerosis in diabetic patients with hypertension.
Supplementary material is linked to the online version of the paper at http:// www.nature.com/ajh
